.jpeg/jcr:content.jpeg)
Vaccines
Please log in or register to continue reading.
Join Dr. Juan Pablo Torres Torretti for an instructive presentation on the real-world implementation and impact of nirsevimab for RSV prevention. Drawing from groundbreaking data from Chile—the first Southern Hemisphere country to implement a nationwide nirsevimab immunization program—Dr. Torres reveals remarkable outcomes including 80-95% reduction in RSV hospitalizations and 85% reduction in PICU admissions. The presentation highlights Chile's successful strategy of protecting both newborns and infants under six months, achieving over 90% coverage rates with an excellent safety profile. Dr. Torres also shares comparative data from other countries including Spain's NIRSE-GAL study, demonstrating consistent effectiveness across different healthcare systems and providing compelling evidence for nirsevimab's role in transforming RSV prevention globally.
Embracing co-circulation of SARS-CoV-2 and Influenza viruses – Influenza vaccination matters
Please log in or register to continue reading.
We are in the midst of verifying your registration. You will receive an email confirmation to access Campus Sanofi once your verification is complete.
Please check you email for verification emali.
You do not have the correct verified role to view this content.
Thank you for registering. Please validate your email by clicking on the link in the email sent to you. Once your registration has been validated, you will receive a confirmation email to log in to Campus Sanofi.